Serum Apo Lipoprotein E, Apo Lipoprotein E Gene Polymorphisms, and Parkinson's Disease.

Background: A central role for apolipoprotein E (APOE) has been suggested in modulating processes of neurodegeneration.

Objective: To study the association between serum APOE levels, APOE gene polymorphisms, and Parkinson's disease (PD).

Material And Methods: Fifty-five patients with PD and 30 healthy subjects were enrolled.

Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis.

Background: Despite multiple diagnostic tests, multiple sclerosis (MS) remains a clinical diagnosis with supportive paraclinical evidence.

Objective: To measure glutamate and nitric oxide serum levels in MS patients during and in between relapses to assess their potential role as biomarkers of disease activity and relapses.

Subjects And Methods: This cross sectional study was carried out on 70 MS patients and 40 age and sex matched apparently healthy controls.

Interleukin-18 promoter polymorphisms and idiopathic Parkinson disease: an Egyptian study.

Etiology of sporadic Parkinson's disease (PD) is largely unknown. The contribution of genetic factors to the pathogenesis of PD is supported by the demonstration of high concordance in twins, increased risk among relatives of PD patients and existence of familial cases. This study aimed to examine the relation between interleukin 18 (IL-18) gene promoter polymorphisms and idiopathic PD, and its impact on clinical presentation and disease severity.

Epilepsy and antiepileptic drugs: risk factors for atherosclerosis.

Introduction: Epilepsy is a chronic disease that affects metabolism either alone or through the antiepileptic drug (AED) treatment. A risk of atherosclerosis has been found in epileptic patients.

Aim: Prove the potential role of epilepsy and/or its treatment as atherosclerotic risk factors.